Cargando…

Circulating MicroRNAs as Biomarkers for Sepsis

Sepsis represents a major cause of lethality during intensive care unit (ICU) treatment. Pharmacological treatment strategies for sepsis are still limited and mainly based on the early initiation of antibiotic and supportive treatment. In this context, numerous clinical and serum based markers have...

Descripción completa

Detalles Bibliográficos
Autores principales: Benz, Fabian, Roy, Sanchari, Trautwein, Christian, Roderburg, Christoph, Luedde, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730322/
https://www.ncbi.nlm.nih.gov/pubmed/26761003
http://dx.doi.org/10.3390/ijms17010078
_version_ 1782412375959273472
author Benz, Fabian
Roy, Sanchari
Trautwein, Christian
Roderburg, Christoph
Luedde, Tom
author_facet Benz, Fabian
Roy, Sanchari
Trautwein, Christian
Roderburg, Christoph
Luedde, Tom
author_sort Benz, Fabian
collection PubMed
description Sepsis represents a major cause of lethality during intensive care unit (ICU) treatment. Pharmacological treatment strategies for sepsis are still limited and mainly based on the early initiation of antibiotic and supportive treatment. In this context, numerous clinical and serum based markers have been evaluated for the diagnosis, the severity, and the etiology of sepsis. However until now, few of these factors could be translated into clinical use. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently it was demonstrated that miRNAs are released into the circulation and that the spectrum of circulating miRNAs might be altered during various pathologic conditions, such as inflammation, infection, and sepsis. By using array- and single PCR-based methods, a variety of deregulated miRNAs, including miR-25, miR-133a, miR-146, miR-150, and miR-223, were described in the context of sepsis. Some of the miRNAs correlated with the disease stage, as well as patients’ short and long term prognosis. Here, we summarize the current findings on the role of circulating miRNAs in the diagnosis and staging of sepsis in critically ill patients. We compare data from patients with findings from animal models and, finally, highlight the challenges and drawbacks that currently prevent the use of circulating miRNAs as biomarkers in clinical routine.
format Online
Article
Text
id pubmed-4730322
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47303222016-02-11 Circulating MicroRNAs as Biomarkers for Sepsis Benz, Fabian Roy, Sanchari Trautwein, Christian Roderburg, Christoph Luedde, Tom Int J Mol Sci Review Sepsis represents a major cause of lethality during intensive care unit (ICU) treatment. Pharmacological treatment strategies for sepsis are still limited and mainly based on the early initiation of antibiotic and supportive treatment. In this context, numerous clinical and serum based markers have been evaluated for the diagnosis, the severity, and the etiology of sepsis. However until now, few of these factors could be translated into clinical use. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently it was demonstrated that miRNAs are released into the circulation and that the spectrum of circulating miRNAs might be altered during various pathologic conditions, such as inflammation, infection, and sepsis. By using array- and single PCR-based methods, a variety of deregulated miRNAs, including miR-25, miR-133a, miR-146, miR-150, and miR-223, were described in the context of sepsis. Some of the miRNAs correlated with the disease stage, as well as patients’ short and long term prognosis. Here, we summarize the current findings on the role of circulating miRNAs in the diagnosis and staging of sepsis in critically ill patients. We compare data from patients with findings from animal models and, finally, highlight the challenges and drawbacks that currently prevent the use of circulating miRNAs as biomarkers in clinical routine. MDPI 2016-01-09 /pmc/articles/PMC4730322/ /pubmed/26761003 http://dx.doi.org/10.3390/ijms17010078 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Benz, Fabian
Roy, Sanchari
Trautwein, Christian
Roderburg, Christoph
Luedde, Tom
Circulating MicroRNAs as Biomarkers for Sepsis
title Circulating MicroRNAs as Biomarkers for Sepsis
title_full Circulating MicroRNAs as Biomarkers for Sepsis
title_fullStr Circulating MicroRNAs as Biomarkers for Sepsis
title_full_unstemmed Circulating MicroRNAs as Biomarkers for Sepsis
title_short Circulating MicroRNAs as Biomarkers for Sepsis
title_sort circulating micrornas as biomarkers for sepsis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730322/
https://www.ncbi.nlm.nih.gov/pubmed/26761003
http://dx.doi.org/10.3390/ijms17010078
work_keys_str_mv AT benzfabian circulatingmicrornasasbiomarkersforsepsis
AT roysanchari circulatingmicrornasasbiomarkersforsepsis
AT trautweinchristian circulatingmicrornasasbiomarkersforsepsis
AT roderburgchristoph circulatingmicrornasasbiomarkersforsepsis
AT lueddetom circulatingmicrornasasbiomarkersforsepsis